Researchers unearth instances of horizontal gene transfer between bacteria used in making cheese, New Scientist reports.
Tufts scientists and their colleagues called for steps to ensure that disadvantaged groups benefit from genetically based diagnoses and treatments.
Metabolon will work with Johns Hopkins University and Tufts Medical Center to develop and clinically validate the new blood-based diagnostic.
Scientists from Tufts and Harvard can efficiently deliver Cas9 to human cells with a lipid nanoparticle technology, setting the stage for in vivo delivery.
As Quanterix continues to grow its business, quantifying proteins in single cells could drive its sales in the academic market, CEO Kevin Hrusovsky said.
The deal provides Tufts Health Plan members with access to the ConfirmMDx test for prostate cancer.
Non-invasive prenatal screening tests are not only detecting fetal chromosomal abnormalities, but also some cases of maternal cancer.
The results are the most comprehensive picture so far of the patterns of abnormal NIPT results that could indicate a woman has a higher risk of carrying an unknown tumor.
Around 70 percent of cancer compounds and 40 percent of compounds for all indications are being developed with biomarker data.
The team's dilution experiments suggest Simoa could be thousands of times more sensitive than standard ELISAs in detecting anti-dengue antibodies.
The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.
A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.
The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.
In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.